Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. What is the incidence of inflammatory bowel disease with Taltz® (ixekizumab)?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the incidence of inflammatory bowel disease with Taltz® (ixekizumab)?

During ixekizumab treatment, monitor for onset or exacerbation of IBD and if IBD occurs, discontinue ixekizumab and initiate appropriate medical management.

US_cFAQ_IXE335_INFLAMMATORY_BOWEL_DISEASE_PsO_PsA_axSpA
US_cFAQ_IXE335_INFLAMMATORY_BOWEL_DISEASE_PsO_PsA_axSpA
en-US

Inflammatory Bowel Disease Summary

Cases of new or exacerbations of Crohn's disease (CD) and ulcerative colitis (UC) have been reported. Overall, these events are uncommon (<1%). Caution should be exercised when prescribing ixekizumab to patients with inflammatory bowel disease (IBD), including CD and UC, and patients should be monitored closely.1 

Patients treated with ixekizumab may be at increased risk of IBD. In clinical trials, CD and UC, including exacerbations, occurred at a greater frequency in the ixekizumab group than the placebo control group.2

During ixekizumab treatment, monitor for onset or exacerbation of IBD and if IBD occurs, discontinue ixekizumab and initiate appropriate medical management.2

In the ixekizumab phase 3 clinical trial program across psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), the overall IBD frequency is reported as uncommon (less than 1%) for the placebo-controlled periods.

The exposure adjusted incidence rate (EAIR) as of March 2022 is

  • 0.2 per 100 patient-years (PY) for the adult psoriasis program as of the 5-year exposure data set (N=6892)
  • 0.1 per 100 PY for the PsA program as of the 3-year exposure data set (N=1401), and
  • 0.8 per 100 PY for the axSpA program as of the 3-year exposure data set (N=932).1,3

Crohn's Disease and Ulcerative Colitis Events

Psoriasis Clinical Trials

Per external adjudication, 31 adult patients with psoriasis had reported cases of IBD which were adjudicated as UC (n=18, IR=0.1 per 100 PY) and CD (n=13, IR=0.1 per 100 PY) across 17 adult psoriasis trials (N=6892 patients with 18,025.7 PY of exposure) as of March 2022 (Summary of Adjudicated Inflammatory Bowel Disease Events in Adult Psoriasis Clinical Trials: Frequency and Exposure-Adjusted Incidence Rates (All Ixekizumab Exposures as of March 2022)). Of the 31 patients with IBD events, 20 discontinued ixekizumab treatment at the discretion of the investigator.1,4

Summary of Adjudicateda Inflammatory Bowel Disease Events in Adult Psoriasis Clinical Trials: Frequency and Exposure-Adjusted Incidence Rates (All Ixekizumab Exposures as of March 2022)1,3,5

 

Induction Periodb

Maintenance Periodc

17 Adult PsO Trials


Placebo
(N=791)

Ixekizumab
(N=2328)

Placebod
(N=402)

Ixekizumab 
(N=824)

All Ixekizumab Exposures 
(N=6892)

Total PY

180

534.5

188.2

627.6

18,025.7

Inflammatory bowel disease, n (%)

0

3 (0.13)

3 (0.75)

4 (0.49)

31 (0.4)d

IR/100 PY

0

0.56

1.59

0.64

0.2

Crohn's disease, n (%) 

0

1 (0.04)

3 (0.75)

1 (0.12)

13 (0.2)

 IR/100 PY

0

0.19

1.59

0.16

0.1

Ulcerative colitis, n (%)

0

2 (0.09)

0

3 (0.36)

18 (0.3)

 IR/100 PY

0

0.37

0

0.48

0.1

Abbreviations: IBD = inflammatory bowel disease; IR = incidence rate; PsO = psoriasis; PY = patient-years.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PYs, and then multiplied by 100.

aData on suspected IBD, as identified by events possibly indicative of ulcerative colitis and Crohn’s disease, were collected and the events were adjudicated by an external Clinical Evaluation Committee with expertise in IBD.

bUNCOVER-1, -2, and -3 (week 0-12).

cUNCOVER-1 and -2 (week 12-60).

dTwenty-six cases were listed as treatment-emergent adverse events of IBD. Five additional cases were listed as adverse events of IBD, and these occurred when patients were not on ixekizumab (either occurring when patients were on placebo during the randomized withdrawal period of UNCOVER-2 [n=2], or during follow-up [1 patient each from UNCOVER-2, UNCOVER-3, and IXORA-R]).

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 17 Adult Psoriasis Trials as of March 2022 summarizes adjudicated IBD events based on self-reported history of IBD from the March 2022 data set. Across the 17 adult psoriasis trials, the number of patients who self-reported a history of IBD was 35. Of the 35 patients with self-reported history of IBD, 31 patients reported no events of IBD during the trials.1

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 17 Adult Psoriasis Trials as of March 20221,3

 

All Ixekizumab Psoriasis Exposures 
(N=6892)

Total Exposure as of March 2022, PY

18,025.7

Patients with a self-reported history of IBD, n (%) 

35 (0.5)a

Total inflammatory bowel disease, n (%) [IR/100 PY]

31 (0.4) [0.2]b

Crohn's disease, n (%) [IR/100 PY]

13 (0.2) [0.1]

Patients with greater than or equal to 1 event and a self-reported history of IBD, n

1

Patients with ≥1 event and no known history of IBD, n

12

Ulcerative colitis, n (%) [IR/100 PY]

18 (0.3) [0.1]

Patients with greater than or equal to 1 event and a self-reported history of IBD, n

3

Patients with ≥1 event and no known history of IBD, n

15

Abbreviations: IBD = inflammatory bowel disease; IR = incidence rate; PY = patient-years.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PYs, and then multiplied by 100.

aOf the 35 patients with self-reported history of IBD, 31 reported no events of IBD during the trials.

bTwenty-six cases were listed as treatment-emergent adverse events of IBD. Five additional cases were listed as adverse events of IBD, and these occurred when patients were not on ixekizumab (either occurring when patients were on placebo during the randomized withdrawal period of UNCOVER-2 [n=2], or during follow-up [1 patient each from UNCOVER-2, UNCOVER-3, and IXORA-R]).

Psoriatic Arthritis Clinical Trials

Per external adjudication, 3 patients with PsA had reported cases of IBD which were adjudicated as UC (n=1, IR=0.0 per 100 PY) and CD (n=2, IR=0.1 per 100 PY) across 4 PsA trials (N=1401 patients with 2248 PY of exposure) as of March 2022 (Summary of Adjudicated Inflammatory Bowel Disease Events in Psoriatic Arthritis Clinical Trials: Frequency and Exposure-Adjusted Incidence Rates (All Ixekizumab Exposures as of March 2022)). Of the 3 patients with IBD events, 1 discontinued ixekizumab treatment at the discretion of the investigator.3,6

Summary of Adjudicateda Inflammatory Bowel Disease Events in Psoriatic Arthritis Clinical Trials: Frequency and Exposure-Adjusted Incidence Rates (All Ixekizumab Exposures as of March 2022)1,3

 

Placebo Through 24 Weeksb
(N=224)

Ixekizumab Through 24 Weeksb
(N=454)

All Ixekizumab Exposures Across 4 Psoriatic Arthritis Trials 
(N=1401)

Total PY

85.7

193.8

2248

Inflammatory bowel disease, n (%)

0

0c

3 (0.2)d,e

IR/100 PY

0

0

0.1

Crohn's disease, n (%)

0

0

2 (0.1)

IR/100 PY

0

0

0.1

Ulcerative colitis, n (%)

0

0

1 (0.1)

IR/100 PY

0

0

0.0

Abbreviations: IBD = inflammatory bowel disease; IR = incidence rate; PY = patient-years.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PYs, and then multiplied by 100.

aData on suspected IBD, as identified by events possibly indicative of ulcerative colitis and Crohn’s disease, were collected and the events were adjudicated by an external Clinical Evaluation Committee with expertise in IBD.

bData are from first 24 weeks of SPIRIT-P1 and SPIRIT-P2 trials.

cOne patient had an anal abscess and anal fistula. This event was considered consistent with IBD, but was not adjudicated as Crohn's disease or ulcerative colitis due to insufficient information.

dOne additional patient had an anal abscess and anal fistula. This event was considered consistent with IBD, but was not adjudicated as Crohn's disease or ulcerative colitis due to insufficient information.

eThree patients had events of IBD confirmed by adjudication. One patient had more than 1 event.

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 4 PsA Trials as of March 2022 summarizes adjudicated IBD events based on self-reported history of IBD from the March 2022 data set. The number of patients with self-reported history was 14 across the 4 PsA trials. None of the 14 patients with self-reported history of IBD reported an IBD event during the trials.1

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 4 PsA Trials as of March 20221,3

All Ixekizumab PsA Exposures
(N=1401)

Total exposure as of March 2022, PY

2248

Patients with a self-reported history of IBD, n (%)

14 (1.0)a

Total inflammatory bowel disease, n (%) [IR/100 PY]

3 (0.2) [0.1]b,c

Crohn’s disease, n (%) [IR/100 PY]

2 (0.1) [0.1]

 Patients with ≥1 event and a self-reported history of IBD, n

0

 Patients with ≥1 event and no known history of IBD, n

2

Ulcerative colitis, n (%) [IR/100 PY]

1 (0.1) [0.0]

Patients with ≥1 event and a self-reported history of IBD, n

0

Patients with ≥1 event and no known history of IBD, n

1

Abbreviations: IBD = inflammatory bowel disease; IR = incidence rate; PY = patient-years.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PYs, and then multiplied by 100.

aNone of the 14 patients with self-reported history of IBD reported an IBD event during the trials.

bOne additional patient had an anal abscess and anal fistula. This event was considered consistent with IBD, but was not adjudicated as Crohn's disease or ulcerative colitis due to insufficient information.

cThree patients had events of IBD confirmed by adjudication. One patient had more than 1 event.

Axial Spondyloarthritis Trials

Per external adjudication, 17 patients had reported cases of IBD which were adjudicated as UC (n=10, IR=0.5 per 100 PY) and CD (n=7, IR=0.3 per 100 PY) across 4 axSpA trials (N=932 patients with 2097.7 PY of exposure) as of March 2022 (Summary of Adjudicated Inflammatory Bowel Disease Events in Axial Spondyloarthritis Trials as of March 2022). Of the 17 patients with IBD events, 9 discontinued ixekizumab treatment at the discretion of the investigator.1,7

Summary of Adjudicateda Inflammatory Bowel Disease Events in Axial Spondyloarthritis Trials as of March 20221,3

Placebo Through 16 Weeksb
(N=294)
Ixekizumab Through 16 Weeksb 
(N=574)
All Ixekizumab Exposures Across 4 axSpA Trials
(N=932)

Total PY

89.9

175.8

2097.7

Inflammatory bowel disease, n (%)

1 (0.3)c,d

5 (0.9)

17 (1.8)e

IR/100 PY

1.1

2.8

0.8

Crohn's disease, n (%)

1 (0.3)f

4 (0.7)

7 (0.8)

IR/100 PY

1.1

2.3

0.3

Ulcerative colitis, n (%)

0

1 (0.2)

10 (1.1)

IR/100 PY

0e

0.6

0.5

Abbreviations: AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis; axSpA = axial spondyloarthritis; CD = Crohn's disease; IBD = inflammatory bowel disease; IR = incidence rate; nr-axSpA = nonradiographic axial spondyloarthritis; PY = patient-years; UC = ulcerative colitis.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PYs, and then multiplied by 100.

aData on suspected IBD, as identified by events possibly indicative of UC and CD, were collected and the events were adjudicated by an external Clinical Evaluation Committee with expertise in IBD.

bData are from first 16 weeks of COAST-V, COAST-W (AS/r-axSpA), and COAST-X (nr-axSpA) trials.

cOne patient from COAST-W was reported as a case of UC and later adjudicated as a case of CD.

dThere was 1 patient from COAST-X with a history of UC and reported as a case of UC but adjudicated as “insufficient information."

eOne additional event occurred during safety follow-up in the COAST Program and is not counted as a TEAE.

fOne patient from COAST-W was reported as a case of UC and later adjudicated as CD.

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 4 axSpA Trials (as of March 2022), summarizes adjudicated IBD events based on self-reported history of IBD from the March 2022 data set. The number of patients with a self-reported history was 30. Of the 30 patients with self-reported history of IBD, 25 patients reported no events of IBD during the trials.1

New Onset and Exacerbation of Crohn’s Disease and Ulcerative Colitis in Patients Treated With Ixekizumab From 4 axSpA Trials (as of March 2022)a,1,3


All Ixekizumab axSpA Exposures
(N=932)

Total exposure as of March 2022, PY

2096.2

Patients with a self-reported history of IBD, n (%)

30 (3.2)b

Total inflammatory bowel disease, n (%) [IR/100 PY]

17 (1.8) [0.8]a

Crohn's disease, n (%) [IR/100 PY]

7 (0.8) [0.3]

Patients with greater than or equal to 1 event and a self-reported history of IBD, n

1

Patients with greater than or equal to 1 event and no known history of IBD, n

6

Ulcerative colitis, n (%) [IR/100 PY]

10 (1.1) [0.5]

Patients with greater than or equal to 1 event and a self-reported history of IBD, n

4

Patients with greater than or equal to 1 event and no known history of IBD, n

6

Abbreviations: axSpA = axial spondyloarthritis; IBD = inflammatory bowel disease; IR = incidence rate; PY = patient-years; TEAE = treatment-emergent adverse event.
Note: Incidence rate was calculated as the total of “definite” and “probable” cases, divided by total PY, and then multiplied by 100.

aOne patient who received placebo in COAST-W reported ulcerative colitis, and was later adjudicated as Crohn's disease. In addition, 1 patient in COAST-X who received placebo had a history of ulcerative colitis and was reported as a case of ulcerative colitis, but was adjudicated as insufficient information.

bTwenty-five of the 30 patients with self-reported history of IBD reported no events of IBD during the trials.

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

3Deodhar A, Blauvelt A, Schwartzman S, et al. Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. Abstract presented at: American College of Rheumatology/ARP - 2022 Annual Scientific Meeting; November 10-14, 2022; Philadelphia, Pennsylvania. Accessed October 5, 2022. https://acrabstracts.org/abstract/long-term-safety-of-ixekizumab-in-adult-patients-with-psoriasis-psoriatic-arthritis-and-axial-spondyloarthritis/

4Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol Ther (Heidelb). 2022;12(6):1431-1446. https://doi.org/10.1007/s13555-022-00743-9

5Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol 2017;76(3);441-448.e2. https://dx.doi.org/10.1016/j.jaad.2016.10.027

6Deodhar AA, Combe B, Accioly AP, et al. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022;81(7):944-950. https://doi.org/10.1136/annrheumdis-2021-222027

7Schwartzman S, Deodhar A, Combe B, et al. Safety profile of ixekizumab for the treatment of psoriatic arthritis and axial spondyloarthritis up to 3 years: an updated integrated safety analysis. Poster presented at: Annual Meeting of the America College of Rheumatology (ACR Convergence Virtual); November 1-10, 2021.

Date of Last Review: February 24, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly